Corporate ActionMay 7, 2026, 04:27 PM
Evommune Raises $117.2M in Private Placement; Q1 Net Loss $(21.7)M
AI Summary
Evommune, Inc. reported a net loss of $21.7 million for the three months ended March 31, 2026, an increase from $14.6 million in the prior year. This increased loss was driven by higher research and development and general and administrative expenses, while license revenue ceased. However, the company significantly strengthened its financial position by raising $117.2 million in net proceeds from a private placement of common stock in February 2026. This capital raise led to a substantial increase in cash, investments, and total assets, with management expecting existing capital to fund operations for at least twelve months.
Key Highlights
- Raised $117.2 million net from private placement of 4.5M common shares in February 2026.
- Net loss for Q1 2026 increased to $(21.7) million from $(14.6) million in Q1 2025.
- Total revenue for Q1 2026 was $0, down from $3.0 million in Q1 2025.
- Research and development expenses rose to $17.3 million in Q1 2026, up from $14.4 million.
- General and administrative expenses increased to $6.6 million in Q1 2026 from $3.7 million.
- Total assets grew to $322.5 million as of March 31, 2026, from $224.9 million at year-end 2025.
- Cash, cash equivalents, and investments totaled $307.0 million as of March 31, 2026.